Acrivon Therapeutics Stock
Acrivon Therapeutics, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Peter Blume-Jensen
- Employees
- 75
- Market cap
- $70 M
- IPO
- 15/11/2022
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for…
Acrivon Therapeutics stock: price history
1D
-6.8%
1W
-14.1%
1M
-3.5%
6M
-7.9%
YTD
-32.0%
1Y
-12.3%
2Y
-78.8%
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~42% stronger price swings than usual
Ask the agents about Acrivon Therapeutics
Analyst assessment of Acrivon Therapeutics
PRICE TARGET LOW
US$17.00
CONSENSUS
US$21.83
MEDIAN
US$20.00
PRICE TARGET HIGH
US$30.00
0
STRONG BUY
9
BUY
1
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 09/01/2026
Acrivon Therapeutics stock metrics
P/E
-0.87
P/B
0.79
EV/EBITDA
-0.39
RETURN ON EQUITY
-20.7%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
60.3%
FLOAT SHARES
25,827,721
AVG. DAILY VOLUME (30D)
304,308
Insider transactions (SEC)
Miller Mary
Levin Michaela
Blume-Jensen Peter
Gamelin Erick
Devroe Eric
Institutional holders
Comparable stocks
Frequently asked questions about Acrivon Therapeutics stock
What does Acrivon Therapeutics do?
Acrivon Therapeutics, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Peter Blume-Jensen, the company employs around 75 people.
The IPO was on 15/11/2022; the stock trades on NASDAQ under the ticker ACRV.
What do analysts say about Acrivon Therapeutics stock?
10 analysts rate the stock, the consensus is Buy (as of 09/01/2026).
The average price target is US$21.83, ranging from US$17.00 to US$30.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does Acrivon Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 42% stronger than usual.
Does Acrivon Therapeutics pay a dividend?
No, Acrivon Therapeutics currently does not pay a dividend.
Which stocks are comparable to Acrivon Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Acrivon Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Acrivon Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.